It is currently unknown whether HIF2α inhibitors (e.g., belzutifan) are effective for SDHB mutant PCPG, but it is plausible that co-operative EPAS1 mutations could make these tumours more sensitive69. This evidence concerns the gene EPAS1 and neoplasm.